Since the thread where I posted all this information is probably not getting much views and I seem to be obsessively pointing people to it I decided to make a separate thread explaining how all this works.
Mu and kappa opiod networks facilitate the basic reward/fear system.
Kappa opioid receptors(KOR) when activated shutdown dopamine in mesolimbic structures = this is the main cause of anhedonia
Kappa opioid receptors upregulate when there is too much dopamine in mesolimbic structures. They do this to tame the neurotoxic dopamine levels. You become more fearful/anxious and this counteracts the extra dopamine from whatever you're pushing into your system(cocaine, morphine)
Thus, kappa opioid network is the main network responsible for facilitating drug tolerance and withdrawal.
Once the drug use is stopped the kappa opioid network remains upregulated causing fear/anxiety(and not even having a source origin as in an event since the the cause was chemical). This state leads to drug relapse.
Tha kappa opioid network downregulates slowly, painfully slowly.
Thus, the only know substances to actually reverse tolerance are kappa opioid agonists.
Only known methods are salvia divinorum or ibogaine. Perhaps low dose ketamine could do it, ketamine does agonize kappa and I fear that the known ketamine afterglow glow effect is due to KOR downregulation, just as is Salvias and Ibogaines. Ibogaine has the extra merit of its metabolite noribogaine I think is an antagonist. So after Ibogaine downregulates it, the metabolite disables it for months.
Kappa antagonists on the other hand should not downregulate KORs it but should simply instantly stop the effect of it being upregulated. Kappa antagonists should immediately kill withdrawal.
Having said that, JDTic as a kappa antagonist infact in a way does downregulate KORs. It corrupts them. Thus the long effect. JDTic AFAIK corrupts receptors so its effects last until your brain grows new ones.
As far as mental health is concerned, most mental disorders are fear/anxiety fueled, these are people who have their kappa opioid system upregulated due to trauma, abuse or genetics. Thus, these chemicals are invaluable to treat the entire pallete of mental disorders.
The list starts with anxiety, anhedonia, depression, compulsions and goes on...
Fear causes anxiety. Anxiety is dopamine in the fear system. Fear also kills dopamine in the reward system. After a while the anxious dopamine causes downregulation of the fear-dopamine channels at which point you become less anxious and more lifeless, learned helplessness. So, you become a zombie, your reward dopamine is locked out by fear. And the same fear can't even produce dopamine to provide anxiety, just lethargy and anhedonia.
As you see, dopamine is just the perception-drive neurotransmitter, be it drive to approach or avoid. Thus stimulants cause anxiety more often than reward and prolonged use causes upregulation of KOR system killing dopamine in mesolimbinc structures leaving the stimulants to increase dopamine only for anxiety purposes eventually leading to paranoia.
The only question is, does the mu opioid system upregulate to counter anxiety-dopamine is does the numbing of anxiety only facilitated by dopamine receptor downregulation. If it does then antagonizing KORs in a state of upregulated MOR would lead the person into mania. This interplay might be the mechanism of bipolar as it obviously provides the mechanism for depression/anhedonia.
So, the KOR system facilitates the basis for depression, anxiety, anhedonia and drug tolerance/withdrawal/dependance. It seems like a miracle. But if you look at studies from way past you'll see that the KOR system was ignored by science for anything other than treating regional pain. They found out early that the pushing the KOR for pain management system doesn't cause tolerance unlike pushing mu opioid with moprhin and such. This is logical the KOR system actually facilitates drug tolerance. But they only started experimenting with KOR for other than pain management in the last few years. Almost all of the studies are still in animal testing phase. Only JDTic had a human trial start and it was halted allegedly due to some people having side-effects of heart arrythmia.
Here's some studies about all this, proving various points I made above. Some of the studies are summary studies that also confim this concept. Also, some of the studies link the KOR system to serotonin and GABA to show why meds that push those have some effects for anxiety. SSRIs antianxiety is iffy and benzos is not but they are sedating and cause dependancy and tolerance.
http://www.ncbi.nlm....pubmed/18395712
Depleting serotonin causes kappa opioid agonists failure to inhibit cocaine effects. I would that in that situation suspect kappa opioid receptors upregulate even further in an effort to try and control reward pathways neurotoxic dopamine levels. Providing serotonin enables kappa opioid network to produce its effects and reduces the need for it to upregulate. That's what I read from this, but it is jumping to conclusions.
My point is trying to link up the iffy efficacy of serotonin for depression/anxiety.
Ok, lets do some more
http://www.ncbi.nlm....pubmed/20939060
Acute activation of κ-opioid receptors (KOR) decreases dopamine (DA) extracellular levels in both the medial prefrontal cortex (mPFC) and the nucleus accumbens (NAc). Also, the acute activation of KOR prevents alterations in behavior and neurochemistry occurring after repeated use of psychostimulants. Opposing to the acute effects, repeated administration of the KOR agonist, U-6593, potentiates both high-potassium and amphetamine induced DA release in the NAc, suggesting that repeated activation of KOR sensitizes mesolimbic dopaminergic neurotransmission. This study investigated the effect of repeated treatment with U-69593 on basal and stimulated DA and serotonin (5HT) extracellular levels in the rat mPFC. Rats were injected once daily with U-69593 (0.16-0.32 mg/kg) or vehicle for 4 days. One day after the last injection, microdialysis experiments assessing DA and 5HT extracellular levels in mPFC were conduced. The repeated treatment with U-69593 significantly augmented potassium-stimulated DA extracellular levels, without affecting potassium-stimulated 5HT extracellular levels, suggesting an increase in DA releasability.
IMO this basicly says: kappa opioid agonists fix anhedonia(dopamine levels in mesolimbic structures) through periodical dosing. (remember what I wrote: salvia divinorum weekly/biweekly)
Not very interesting but still another study that proves the mechanism: http://www.ncbi.nlm....pubmed/19859697
But here we go in longecity style:
Knockdown of prodynorphin gene prevents cognitive decline, reduces anxiety, and rescues loss of group 1 metabotropic glutamate receptor function in aging. http://www.ncbi.nlm....pubmed/23904614
Prodynorphin is the precursor to dynorphin - the endogenous kappa opioid ligand
More,
Collectively, available data suggest that KOR disruption produces anti-stress effects and under some conditions can prevent the development of stress-induced adaptations. As such, KOR antagonists may have unique potential as therapeutic agents for the treatment and even prevention of stress-related psychiatric illness, a therapeutic niche that is currently unfilled
http://www.ncbi.nlm....pubmed/23836029
More
Together these data demonstrate that CeA dynorphin/KOR systems are dysregulated following excessive cocaine exposure and suggest KOR antagonism as a viable therapeutic strategy for cocaine addiction.
http://www.ncbi.nlm....pubmed/23751206
And more rats
Rats with a history of ethanol dependence showed a significant decrease in open-arm exploration after exposure to restraint, indicating an anxiety-like state, compared to similarly treated controls, an effect that was blocked by nor-BNI
http://www.ncbi.nlm....pubmed/23731692
nor-BNI is kappa opioid antagonist
Kappa opioid receptor signaling in the basolateral amygdala regulates conditioned fear and anxiety in rats.
http://www.ncbi.nlm....pubmed/21531393
Blockade of kappa opioid receptors attenuates the development of depressive-like behaviors induced by cocaine withdrawal in rats
http://www.ncbi.nlm....pubmed/21736885
This one just to connect to the standard benzo anxiety treatment:
Presynaptic inhibition of gamma-aminobutyric acid release in the bed nucleus of the stria terminalis by kappa opioid receptor signaling
http://www.ncbi.nlm....pubmed/22225848
GABA is just an infrastructure network. KOR inhibits GABA. So taking GABAergics is fixing the issue downstream of the source. As are dopaminergics and serotonergics.
One for the topic at hand:
The kappa opioid receptor antagonist JDTic attenuates alcohol seeking and withdrawal anxiety.
http://www.ncbi.nlm....pubmed/22515275
One summary study saying exactly what I'm saying:
Addictions to cocaine or heroin/prescription opioids [short-acting μ-opioid receptor (MOPr) agonists] involve relapsing cycles, with experimentation/escalating use, withdrawal/abstinence, and relapse/re-escalation. κ-Opioid receptors (KOPr; encoded by OPRK1), and their endogenous agonists, the dynorphins (encoded by PDYN), have counter-modulatory effects on reward caused by cocaine or MOPr agonist exposure, and exhibit plasticity in addictive-like states. KOPr/dynorphin activation is implicated in depression/anxiety, often comorbid with addictions. In this opinion article we propose that particular stages of the addiction cycle are differentially affected by KOPr/dynorphin systems. Vulnerability and resilience can be due to pre-existing (e.g., genetic) factors, or epigenetic modifications of the OPRK1 or PDYN genes during the addiction cycle. Pharmacotherapeutic approaches limiting changes in KOPr/dynorphin tone, especially with KOPr partial agonists, may hold potential for the treatment of specific drug addictions and psychiatric comorbidity.
http://www.ncbi.nlm....pubmed/22709632
Another withdrawal, this time nicotine
Chronic nicotine enhanced the affective, anxiogenic, and neurochemical effects produced by KOR activation in adult rats. Our data suggest that chronic nicotine elicits an increase in KOR function, and this may contribute to nicotine withdrawal since KOR activation facilitated and KOR blockade prevented withdrawal signs upon removal of nicotine.
http://www.ncbi.nlm....pubmed/22659976
One general, proving that dynorphin regulates fear acquiring and extinction:
Dynorphins regulate fear memory: from mice to men.
http://www.ncbi.nlm....pubmed/22764240
Antidepressant-like effects of kappa-opioid receptor antagonists in Wistar Kyoto rats.
http://www.ncbi.nlm....pubmed/19924112
Another summary study:
Stress is most often associated with aversive states. It rapidly induces the release of hormones and neuropeptides including dynorphin, which activates kappa opioid receptors (KORs) in the central and peripheral nervous systems. In animal models, many aversive effects of stress are mimicked or exacerbated by stimulation of KORs in limbic brain regions. Although KOR signaling during acute stress may increase physical ability (by producing analgesia) and motivation to escape a threat (by producing aversion), prolonged KOR signaling in response to chronic or uncontrollable stress can lead to persistent expression of behavioral signs that are characteristic of human depressive disorders (i.e., "prodepressive-like" signs). Accumulating evidence suggests that KORs contribute to the progressive amplification (sensitization) of stress-induced behaviors that occurs with repeated exposure to stress. Many of the aversive effects of stress are blocked by KOR antagonists, suggesting that these agents may have potential as therapeutics for stress-related conditions such as depression and anxiety disorders. This review summarizes current data on how KOR systems contribute to the acute (rapid), delayed, and cumulative molecular and behavioral effects of stress. We focus on behavioral paradigms that provide insight on interactions between stress and KOR function within each of these temporal categories. Using a simplified model, we consider the time course and mechanism of KOR-mediated effects in stress and suggest future directions that may be useful in determining whether KOR antagonists exert their therapeutic effects by preventing the development of stress-induced behaviors, the expression of stress-induced behaviors, or both.
http://www.ncbi.nlm....pubmed/19782055
AAAAnd I didnt read this study before writing all this but here it is, like someone read my threads from various forums:
The dynorphin-like peptides have profound effects on the state of the brain reward system and human and animal behavior. The dynorphin-like peptides affect locomotor activity, food intake, sexual behavior, anxiety-like behavior, and drug intake. Stimulation of kappa-opioid receptors, the endogenous receptor for the dynorphin-like peptides, inhibits dopamine release in the striatum (nucleus accumbens and caudate putamen) and induces a negative mood state in humans and animals. The administration of drugs of abuse increases the release of dopamine in the striatum and mediates the concomitant release of dynorphin-like peptides in this brain region. The reviewed studies suggest that chronic drug intake leads to an upregulation of the brain dynorphin system in the striatum and in particular in the dorsal part of the striatum/caudate putamen. This might inhibit drug-induced dopamine release and provide protection against the neurotoxic effects of high dopamine levels. After the discontinuation of chronic drug intake these neuroadaptations remain unopposed which has been suggested to contribute to the negative emotional state associated with drug withdrawal and increased drug intake.
http://www.ncbi.nlm....pubmed/19804796
And for all ADHD treated kids:
Kappa-opioid system regulates the long-lasting behavioral adaptations induced by early-life exposure to methylphenidate.
http://www.ncbi.nlm....pubmed/18923399
So there, we have it all covered, all addictions, depression, anhedonia and anxiety. And the underlying mechanism. And even some relations to why current medication semi-works.
So, I can't really find anything that doesn't support this concept. I would value someone actually trying to follow me on this and see how correct this really is because I'm either insane or brilliant and I have been both in the past so...
Comments welcome